These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 22789536

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
    Okuda T, Tasaki T, Nakata S, Yamashita K, Yoshioka H, Izumoto S, Kato A, Fujita M.
    Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
    Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK.
    J Clin Oncol; 2015 Apr 01; 33(10):1197-213. PubMed ID: 25713439
    [Abstract] [Full Text] [Related]

  • 9. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.
    Gortany NK, Panahi G, Ghafari H, Shekari M, Ghazi-Khansari M.
    Cancer Chemother Pharmacol; 2021 Jun 01; 87(6):827-842. PubMed ID: 33688998
    [Abstract] [Full Text] [Related]

  • 10. Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition.
    Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF.
    Clin Cancer Res; 2013 Aug 15; 19(16):4392-403. PubMed ID: 23804423
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
    Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K, Yao J, Priebe W, Colman H, Elferink LA, Bogler O.
    Neoplasia; 2013 Jan 15; 15(1):73-84. PubMed ID: 23359207
    [Abstract] [Full Text] [Related]

  • 13. 17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion.
    Miekus K, Kijowski J, Sekuła M, Majka M.
    Oncol Rep; 2012 Nov 15; 28(5):1903-9. PubMed ID: 22941268
    [Abstract] [Full Text] [Related]

  • 14. Role of protein tyrosine phosphatase 1B in vascular endothelial growth factor signaling and cell-cell adhesions in endothelial cells.
    Nakamura Y, Patrushev N, Inomata H, Mehta D, Urao N, Kim HW, Razvi M, Kini V, Mahadev K, Goldstein BJ, McKinney R, Fukai T, Ushio-Fukai M.
    Circ Res; 2008 May 23; 102(10):1182-91. PubMed ID: 18451337
    [Abstract] [Full Text] [Related]

  • 15. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
    Furuta T, Nakada M, Misaki K, Sato Y, Hayashi Y, Nakanuma Y, Hamada J.
    Brain Tumor Pathol; 2014 Jan 23; 31(1):32-9. PubMed ID: 23504126
    [Abstract] [Full Text] [Related]

  • 16. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
    Pillay V, Allaf L, Wilding AL, Donoghue JF, Court NW, Greenall SA, Scott AM, Johns TG.
    Neoplasia; 2009 May 23; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
    [Abstract] [Full Text] [Related]

  • 17. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
    Moriyama T, Kataoka H, Koono M, Wakisaka S.
    Int J Mol Med; 1999 May 23; 3(5):531-6. PubMed ID: 10202187
    [Abstract] [Full Text] [Related]

  • 18. Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation.
    Murray DW, Didier S, Chan A, Paulino V, Van Aelst L, Ruggieri R, Tran NL, Byrne AT, Symons M.
    Br J Cancer; 2014 Mar 04; 110(5):1307-15. PubMed ID: 24518591
    [Abstract] [Full Text] [Related]

  • 19. Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions.
    Al-Ghabkari A, Huang B, Park M.
    Cells; 2024 Jan 25; 13(3):. PubMed ID: 38334610
    [Abstract] [Full Text] [Related]

  • 20. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G, Narayan RN, Horton L, Patel TR, Habib AA.
    Curr Cancer Drug Targets; 2017 Jan 25; 17(3):297-302. PubMed ID: 28004613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.